LEO Pharma A/S – Product Pipeline Review

Global Markets Direct’s, ‘LEO Pharma A/S – Product Pipeline Review – 2016’, provides an overview of the LEO Pharma A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by LEO Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of LEO Pharma A/S

The report provides overview of LEO Pharma A/S including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses LEO Pharma A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features LEO Pharma A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate LEO Pharma A/S’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for LEO Pharma A/S

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding LEO Pharma A/S’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

LEO Pharma A/S Snapshot 6

LEO Pharma A/S Overview 6

Key Information 6

Key Facts 6

LEO Pharma A/S - Research and Development Overview 7

Key Therapeutic Areas 7

LEO Pharma A/S - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

LEO Pharma A/S - Pipeline Products Glance 15

LEO Pharma A/S - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

LEO Pharma A/S - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

LEO Pharma A/S - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

LEO Pharma A/S - Drug Profiles 21

(betamethasone dipropionate + calcipotriene) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

LEO-43204 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

aprepitant 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ingenol mebutate 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

LEO-124249 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

LP-0113 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

LEO-130852A 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

LEO-32731 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

LEO-39652 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

VBY-891 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

LP-0067 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Antagonize MCHR1 for Weight Loss 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules to Activate Protein Kinase C for Dermatology and Oncology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

LEO Pharma A/S - Pipeline Analysis 35

LEO Pharma A/S - Pipeline Products by Target 35

LEO Pharma A/S - Pipeline Products by Route of Administration 37

LEO Pharma A/S - Pipeline Products by Molecule Type 38

LEO Pharma A/S - Pipeline Products by Mechanism of Action 39

LEO Pharma A/S - Recent Pipeline Updates 40

LEO Pharma A/S - Dormant Projects 43

LEO Pharma A/S - Discontinued Pipeline Products 44

Discontinued Pipeline Product Profiles 44

(calcipotriene + hydrocortisone butyrate) 44

TD-1414 44

LEO Pharma A/S - Company Statement 45

LEO Pharma A/S - Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

LEO Pharma A/S, Key Information 6

LEO Pharma A/S, Key Facts 6

LEO Pharma A/S – Pipeline by Indication, 2016 9

LEO Pharma A/S – Pipeline by Stage of Development, 2016 10

LEO Pharma A/S – Monotherapy Products in Pipeline, 2016 11

LEO Pharma A/S – Combination Treatment Modalities in Pipeline, 2016 12

LEO Pharma A/S – Partnered Products in Pipeline, 2016 13

LEO Pharma A/S – Partnered Products/ Combination Treatment Modalities, 2016 14

LEO Pharma A/S – Pre-Registration, 2016 15

LEO Pharma A/S – Phase III, 2016 16

LEO Pharma A/S – Phase II, 2016 17

LEO Pharma A/S – Phase I, 2016 18

LEO Pharma A/S – Preclinical, 2016 19

LEO Pharma A/S – Discovery, 2016 20

LEO Pharma A/S – Pipeline by Target, 2016 36

LEO Pharma A/S – Pipeline by Route of Administration, 2016 37

LEO Pharma A/S – Pipeline by Molecule Type, 2016 38

LEO Pharma A/S – Pipeline Products by Mechanism of Action, 2016 39

LEO Pharma A/S – Recent Pipeline Updates, 2016 40

LEO Pharma A/S – Dormant Developmental Projects,2016 43

LEO Pharma A/S – Discontinued Pipeline Products, 2016 44

LEO Pharma A/S, Subsidiaries 46

List of Figures

List of Figures

LEO Pharma A/S – Pipeline by Top 10 Indication, 2016 8

LEO Pharma A/S – Pipeline by Stage of Development, 2016 10

LEO Pharma A/S – Monotherapy Products in Pipeline, 2016 11

LEO Pharma A/S – Partnered Products in Pipeline, 2016 13

LEO Pharma A/S – Pipeline by Top 10 Target, 2016 35

LEO Pharma A/S – Pipeline by Route of Administration, 2016 37

LEO Pharma A/S – Pipeline by Molecule Type, 2016 38

LEO Pharma A/S – Pipeline Products by Top 10 Mechanism of Action, 2016 39

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports